A look back at the most influential drug approvals of 2005.
Laustsen
Gary
G
Regis University, Denver Colo., USA.
Gilbert
Marcia
M
Wimett
Lynn
L
D000682:Amyloid / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology; D017277:Drug Approval; D004338:Drug Combinations; D004358:Drug Therapy / Q000451:nursing / Q000639:trends*; D064420:Drug-Related Side Effects and Adverse Reactions; D000077270:Exenatide; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007192:Indenes / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D058228:Islet Amyloid Polypeptide; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D010353:Patient Education as Topic; D018579:Patient Selection; D010455:Peptides / Q000627:therapeutic use; D000069583:Pregabalin; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration; D014688:Venoms / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000682:Amyloid; D000700:Analgesics; D000927:Anticonvulsants; D000978:Antiparkinson Agents; C505143:Boostrix; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D007192:Indenes; D007211:Indoles; D058228:Islet Amyloid Polypeptide; D010455:Peptides; D014688:Venoms; C431665:isosorbide-hydralazine combination; C046649:ropinirole; D006830:Hydralazine; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; C495910:ramelteon; D000077270:Exenatide; C105254:pramlintide; D007548:Isosorbide Dinitrate